NASDAQ:ELDN

Eledon Pharmaceuticals Q3 2025 Earnings Results & Report

Eledon Pharmaceuticals logo
$1.78 -0.12 (-6.32%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.79 +0.01 (+0.73%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eledon Pharmaceuticals beat analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$0.21 versus the -$0.22 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
4:00 PM ET

Eledon Pharmaceuticals EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.22
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Eledon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eledon Pharmaceuticals Q3 2025 Earnings FAQ

Eledon Pharmaceuticals (NASDAQ:ELDN) reported earnings of -$0.21 per share for Q3 2025, beating the consensus estimate of -$0.22. The report was announced on Friday, November 14, 2025.

Eledon Pharmaceuticals Earnings Headlines

What is Noble Financial's Estimate for ELDN FY2026 Earnings?
Eledon Pharmaceuticals (NASDAQ:ELDN) Raised to Sell at Wall Street Zen
$0. Later: $29.97.
Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
See More Eledon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company’s research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS).

Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS. The therapy is experimental and has not been approved for commercial use.

Eledon is headquartered in Irvine, California. The company’s work is focused on research and clinical development; it does not currently offer an approved commercial product.

View Eledon Pharmaceuticals Profile